Novonesis provides outlook for 2024 with expected 5-7% organic sales growth and ~35% adj. EBITDA margin. Pro forma financials disclosed. Ester Baiget, CEO of Novonesis, said: “Today we provide key pro ...
The MarketWatch News Department was not involved in the creation of this content. SINGAPORE, Aug. 29, 2025 (GLOBE NEWSWIRE) -- GCL Global Holdings Ltd (NASDAQ: GCL) ("GCL" or the "Company"), a leading ...
Hosted on MSN
RedHill Biopharma files pro forma financials after Talicia joint venture deal with Cumberland
The latest announcement is out from RedHill Biopharma ( (RDHL)). On October 17, 2025, RedHill Biopharma completed a strategic transaction with Cumberland Pharmaceuticals involving Talicia®, its ...
The unaudited pro forma condensed combined statements of income and comprehensive income combine the audited consolidated statement of income and comprehensive income of GCL for the year ended March ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results